Effect of carvedilol and metoprolol on the mode of death in patients with heart failure

European Journal of Heart Failure

Volumn 9, Issue 11, 2007, Pages 1128-1135

  Remme, Willem J ^a   Cleland, John G ^b   Erhardt, Leif ^c   Spark, Phillip ^d   Torp Pedersen, Christian ^e   Metra, Marco ^f   Komajda, Michel ^g   Moullet, Christine ^h   Lukas, Mary Ann ⁱ   Poole Wilson, Philip ^j   Di Lenarda, Andrea ^k   Swedberg, Karl ^l  

^a Sticares Cardiovascular Research Foundation   (Netherlands)

^b UNIVERSITY OF HULL   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Nottingham Clinical Research Group   (United Kingdom)

^e BISPEBJERG HOSPITAL   (Denmark)

^f UNIVERSITY OF BRESCIA   (Italy)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ GLAXOSMITHKLINE   (United States)

^j NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^k UNIVERSITY OF TRIESTE   (Italy)

^l SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

blockade; Cardiovascular mortality; Circulatory failure death; Heart failure; Stroke death; Sudden death

Indexed keywords

CARVEDILOL; METOPROLOL TARTRATE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STROKE; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; AGED; CARBAZOLES; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PROPANOLAMINES; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 35548981390     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.07.014     Document Type: Article

References (21)

1. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 353 (1999) 9-13
2. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in congestive heart failure (MERIT-HF). Lancet 353 (1999) 2001-2007
4. Packer M., Coats A.J.S., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
5. Flather M., Shibata M., Coats A., et al. Randomised trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
6. Poole-Wilson P.A., Swedberg K., Cleland J.G.F., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
7. Poole-Wilson P.A., Cleland J.G., Di Lenarda A., et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur Heart J 4 (2002) 321-329
8. Wei L.J., Lin D.Y., and Weissfeld L. Regression analysis of multivariate incomplete failure time data by modelling marginal distribution. J Am Stat Assoc 84 (1989) 1065-1073
9. Remme W.J., Cleland J.G., Di Lenarda A., et al. Carvedilol better protects against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol 49 (2007) 963-971
10. Di Lenarda A., Sabbadini G., Salvatore L., et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle-Disease Study Group. J Am Coll Cardiol 33 (1999) 1926-1934
11. Metra M., Gibbini R., Nodari S., Boldi E., Modena M.G., and Dei Cas L. Differential effects of beta-blockers in patients with heart failure. A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102 (2002) 546-551
12. Packer M., Antonopoulos G.V., Berlin J.A., Chittams J., Konstam M.A., and Udelson J.E. Comparative effects or carvedilol and metoprolol on left ventricular ejection fraction in heart failure: a meta-analysis. Am Heart J 141 (2001) 899-907
13. Azevedo E.R., Kubo T., Mak S., et al. Nonselective versus selective β-adrenergic receptor blockade in congestive heart failure. Differential effects on sympathetic activity. Circulation 104 (2001) 2194-2199
14. Gilbert E.M., Abraham W.T., Olsen S., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94 (1996) 2817-2825
15. Kurz T., Richardt D., Gorge B., et al. Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart. J Cardiovasc Pharmacol 36 (2000) 96-100
16. Kindermann M., Maack C., Schaller S., et al. Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 109 (2004) 3182-3189
17. Di Lenarda A., Remme W.J., Charlesworth A., et al. Exchange of β-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Fail 7 (2005) 640-649
18. Piccirillo G., Quaglione R., Nocco M., et al. Effects of long-term beta-blocker metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol 90 (2002) 1113-1117
19. Uretsky B.F., Thygesen K., Armstrong P.W., et al. Acute coronary findings at autopsy in heart failure patients with sudden death. Results from the Assessment and Treatment with Lisinopril And Survival (ATLAS) trial. Circulation 102 (2000) 611-616
20. Torp-Pedersen C., Poole-Wilson P.A., Swedberg K., et al. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure - COMET. Am Heart J 149 (2005) 370-376
21. Metra M., Torp-Pedersen C., Swedberg K., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results of the COMET trial. Eur Heart J 26 (2005) 2259-2268